Neuro-oncology practice最新文献

{"title":"Perceptions and experiences of the subjective well-being of people with glioblastoma: a longitudinal phenomenological study.","authors":"Katie Sutton,&nbsp;Jaqualyn Moore,&nbsp;Jo Armes,&nbsp;Emma Briggs","doi":"10.1093/nop/npac064","DOIUrl":"https://doi.org/10.1093/nop/npac064","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM) is a devastating form of brain cancer, with a short life expectancy. In addition to this poor prognosis, people with GBM often experience symptoms that may have a profound impact on their subjective well-being (SWB). The aim of this study was to investigate the lived experiences and perceptions of people with GBM regarding their SWB.</p><p><strong>Methods: </strong>The study adopted a longitudinal, hermeneutical phenomenological approach. Twenty-seven interviews were conducted with 15 patients over a period of two years. Most participants were interviewed twice on a face-to-face basis (during combined chemotherapy and radiotherapy, and again during adjuvant chemotherapy). The hermeneutic circle was used to guide data analysis.</p><p><strong>Results: </strong>Data analysis identified four key themes that depicted the lived experiences and perceptions of SWB of people with GBM. \"Experience of the disease\" focuses on the impact of diagnosis, symptoms and side effects. \"Daily life\" relates to daily activities, family roles, work and social lives. \"Coping\" includes the importance of normality and goal-setting. \"Experiences of care\" focuses on the impact of the treatment schedule, experiences of care and impressions of the monitoring of QoL.</p><p><strong>Conclusion: </strong>SWB is affected by a variety of factors throughout the GBM disease and treatment journey. The findings of this study suggest that healthcare professionals can enhance the SWB of people with GBM by providing personalized care that supports people to set themselves goals for the future and retain a degree of normality wherever possible.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"79-88"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9114834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the incidence of malignant central nervous system tumors in Brazil, 2000-2015.","authors":"Letícia Lima de Oliveira,&nbsp;Anke Bergmann,&nbsp;Luiz Claudio Santos Thuler","doi":"10.1093/nop/npac063","DOIUrl":"https://doi.org/10.1093/nop/npac063","url":null,"abstract":"<p><strong>Background: </strong>In Brazil, 5870 new cases of malignant central nervous system tumors (MCNST) were estimated for men and 5220 for women for each year of the 2020-2022 triennium. The objective of this study was to analyze incidence rate trends and compare demographic characteristics of new MCNST cases according to tumor topographies in Brazil from 2000 to 2015.</p><p><strong>Methods: </strong>This study comprises an analytical cross-sectional assessment of secondary databases extracted from the Brazilian National Cancer Institute (INCA) website. Data comprised new neoplasm cases of meninges (C70), brain (C71), spinal cord, cranial nerves, and other central nervous system parts (C72) retrieved from 23 population-based cancer registries. A descriptive analysis was performed. Crude and age-adjusted incidence rates were calculated. Linear trends were calculated using a linear least squares regression for adjusted incidence rates versus time.</p><p><strong>Results: </strong>A total of 24 986 new MCNST cases were recorded. The main topography was the brain (91.5%). Except for meninges tumors, where 62.4% of the cases were observed in women, MCNST cases were more frequent among men concerning the other evaluated topographies. All 3 topographies occurred predominantly in adult patients aged from 40- to 64-year-old. Between 2000 and 2015, incidence rates ranged from 5.12 to 4.95 (a 1.4% increase of per year; 95% CI -4.0 to 6.8; <i>P</i> = .584) in men and from 4.35 to 3.61 (a 3.1% increase per year; 95% CI -1.7 to 8.0; <i>P</i> = .189).</p><p><strong>Conclusions: </strong>The most frequent topography was the brain. Incidence rates of MCNST remained relatively stable over time in both sexes.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"34-40"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837770/pdf/npac063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10021447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma.","authors":"Angela Sekely,&nbsp;Lori J Bernstein,&nbsp;Kristin L Campbell,&nbsp;Warren P Mason,&nbsp;Normand Laperriere,&nbsp;Navya Kalidindi,&nbsp;Rosemarylin Or,&nbsp;Ronald Ramos,&nbsp;Seth A Climans,&nbsp;Gregory R Pond,&nbsp;Barbara Ann Millar,&nbsp;David Shultz,&nbsp;Derek S Tsang,&nbsp;Gelareh Zadeh,&nbsp;Kim Edelstein","doi":"10.1093/nop/npac068","DOIUrl":"https://doi.org/10.1093/nop/npac068","url":null,"abstract":"<p><strong>Background: </strong>In addition to poor survival rates, individuals with glioblastoma (GBM) are at risk of neurocognitive impairment due to multiple factors. This study aimed to characterize neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in newly diagnosed GBM patients; and to examine whether neurobehavioral symptoms, fatigue, sleep, and depressive symptoms influence neurocognitive performance.</p><p><strong>Methods: </strong>This study was part of a prospective, inception cohort, single-arm exercise intervention in which GBM patients underwent a neuropsychological assessment shortly after diagnosis (median 4 weeks; ie, baseline) and 3, 6, 12, and 18 months later, or until tumor progression. Here, we present baseline data. Forty-five GBM patients (mean age = 55 years) completed objective neurocognitive tests, and self-report measures of neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms.</p><p><strong>Results: </strong>Compared to normative samples, GBM patients scored significantly lower on all neurocognitive tests, with 34 (76%) patients exhibiting neurocognitive impairment. Specifically, 53% exhibited impairment in memory retention, 51% in executive function, 42% in immediate recall, 41% in verbal fluency, and 24% in attention. There were high rates of clinically elevated sleep disturbance (70%), fatigue (57%), depressive symptoms (16%), and neurobehavioral symptoms (27%). A multivariate regression analysis revealed that depressive symptoms are significantly associated with neurocognitive impairment.</p><p><strong>Conclusions: </strong>GBM patients are vulnerable to adverse outcomes including neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms shortly after diagnosis, prior to completing chemoradiation. Those with increased depressive symptoms are more likely to demonstrate neurocognitive impairment, highlighting the need for early identification and treatment of depression in this population.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"89-96"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837779/pdf/npac068.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10280730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of the utilization of telemedicine for brain tumor neurosurgery follow-up.","authors":"Alexis A Morell,&nbsp;Nitesh V Patel,&nbsp;Tiffany A Eatz,&nbsp;Adam S Levy,&nbsp;Daniel G Eichberg,&nbsp;Ashish H Shah,&nbsp;Evan Luther,&nbsp;Victor M Lu,&nbsp;Michael Kader,&nbsp;Dominique M O Higgins,&nbsp;Michael E Ivan,&nbsp;Ricardo J Komotar","doi":"10.1093/nop/npac060","DOIUrl":"https://doi.org/10.1093/nop/npac060","url":null,"abstract":"<p><strong>Background: </strong>There is a need to evaluate the outcomes of patients who underwent brain tumor surgery with subsequent telemedicine or in-person follow-up during the COVID-19 pandemic.</p><p><strong>Methods: </strong>We retrospectively included all patients who underwent surgery for brain tumor resection by a single neurosurgeon at our Institution from the beginning of the COVID-19 pandemic restrictions (March 2020) to August 2021. Outcomes were assessed by stratifying the patients using their preference for follow-up method (telemedicine or in-person).</p><p><strong>Results: </strong>Three-hundred and eighteen (318) brain tumor patients who were included. The follow-up method of choice was telemedicine (TM) in 185 patients (58.17%), and in-person (IP) consults in 133 patients. We found that patients followed by TM lived significantly farther, with a median of 36.34 miles, compared to a median of 22.23 miles in the IP cohort (<i>P</i> = .0025). We found no statistical difference between the TM and the IP group, when comparing visits to the emergency department (ED) within 30 days after surgery (7.3% vs 6.01%, <i>P</i> = .72). Readmission rates, wound infections, and 30-day mortality were similar in both cohorts. These findings were also consistent after matching cohorts using a propensity score. The percentage of telemedicine follow-up consults was higher in the first semester (73.17%) of the COVID-19 pandemic, compared to the second (46.21%), and third semesters (47.86%).</p><p><strong>Conclusions: </strong>Telehealth follow-up alternatives may be safely offered to patients after brain tumor surgery, thereby reducing patient burden in those with longer distances to the hospital or special situations as the COVID-19 pandemic.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"97-103"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10555120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviewer List for the year 2022.","authors":"","doi":"10.1093/nop/npad001","DOIUrl":"https://doi.org/10.1093/nop/npad001","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"107"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10556726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT).","authors":"Son Tran, Ashley S Plant-Fox, Susan N Chi, Aru Narendran","doi":"10.1093/nop/npad005","DOIUrl":"10.1093/nop/npad005","url":null,"abstract":"<p><p>Atypical teratoid rhabdoid tumors (ATRT) are rare and aggressive embryonal tumors of central nervous system that typically affect children younger than 3 years of age. Given the generally poor outcomes of patients with ATRT and the significant toxicities associated with conventional multi-modal therapies, there is an urgent need for more novel approaches to treat ATRT, one such approach being immunotherapy. The recent rise of large-scale, multicenter interdisciplinary studies has delineated several molecular and genetic characteristics unique to ATRT. This review aims to describe currently available data on the tumor immune microenvironment of ATRT and its specific subtypes and to summarize the emerging clinical and preclinical results of immunotherapy-based approaches. It will also highlight the evolving knowledge of epigenetics on immunomodulation in this epigenetically influenced tumor, which may help guide the development of effective immunotherapeutic approaches in the future.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 4","pages":"322-334"},"PeriodicalIF":2.7,"publicationDate":"2023-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9881000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling.","authors":"Maximilian Deng, Felix Hinz, Semi Harrabi, Dominik Sturm, Martin Sill, Andrey Korshunov, Tanja Eichkorn, Juliane Hörner-Rieber, Klaus Herfarth, Christine Jungk, Andreas Unterberg, Stefan Pfister, Wolfgang Wick, Andreas von Deimling, David Jones, Jürgen Debus, Felix Sahm, Laila König","doi":"10.1093/nop/npad004","DOIUrl":"10.1093/nop/npad004","url":null,"abstract":"<p><strong>Background: </strong>Molecular brain tumor classification using DNA methylation profiling has revealed that the methylation-class of pleomorphic xanthoastrocytoma (mcPXA) comprised a substantial portion of divergent initial diagnoses, which had been established based on histology alone. This study aimed to characterize the survival outcome in patients with mcPXAs-in light of the diverse selected treatment regimes.</p><p><strong>Methods: </strong>A retrospective cohort of adult mcPXAs were analyzed in regard to their progression-free survival following surgical resection and postoperative radiotherapy. Radiotherapy treatment plans were correlated with follow-up images to characterize the pattern of relapse. Treatment toxicities and molecular tumor characteristics were further analyzed.</p><p><strong>Results: </strong>Divergent initial histological diagnoses were encountered in 40.7%. There was no significant difference in local progression-free (PFS) and overall survival (OS) following gross total or subtotal resection. Postoperative radiotherapy was completed in 81% (22/27) following surgical intervention. Local PFS was 54.4% (95% CI: 35.3-84.0%) and OS was 81.3% (95% CI: 63.8-100%) after 3 years following postoperative radiotherapy. Initial relapses post-radiotherapy were primarily located in the previous tumor location and/or the planning target volume (PTV) (12/13). All patients in our cohort demonstrated the prognostically favorable <i>pTERT</i>-wildtype mcPXA.</p><p><strong>Conclusion: </strong>Our study demonstrated that adult patients with mcPXAs display a worse progression-free survival compared to the reported WHO grade 2 PXAs. Future matched-pair analyses are required with a non-irradiated cohort to elucidate the benefit of postoperative radiotherapy in adult patients with mcPXAs.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 3","pages":"307-314"},"PeriodicalIF":2.7,"publicationDate":"2023-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9530410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling bias in survival of patients with incidentally discovered low-grade gliomas.","authors":"Derek R Johnson","doi":"10.1093/nop/npad002","DOIUrl":"10.1093/nop/npad002","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"109-110"},"PeriodicalIF":2.7,"publicationDate":"2023-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9246418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forthcoming Meetings","authors":"","doi":"10.1093/nop/npac096","DOIUrl":"https://doi.org/10.1093/nop/npac096","url":null,"abstract":"Journal Article Forthcoming Meetings Get access Neuro-Oncology Practice, Volume 10, Issue 1, February 2023, Page 108, https://doi.org/10.1093/nop/npac096 Published: 13 January 2023 Article history Corrected and typeset: 13 January 2023 Published: 13 January 2023","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135898516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iatrogenic immunodeficiency-associated lymphoproliferative disorders of the central nervous system: a treatment paradox.","authors":"Ramya Tadipatri, Chukwuyem Ekhator, Ram Narayan, Amir Azadi, Kevin C J Yuen, Jai Grewal, Ekokobe Fonkem","doi":"10.1093/nop/npac098","DOIUrl":"10.1093/nop/npac098","url":null,"abstract":"<p><strong>Background: </strong>Primary central nervous system lymphomas (PCNSLs) have historically had dismal survival rates until the advent of high-dose methotrexate (HD-MTX) based chemotherapy regimens. With increasing prevalence of autoimmune disease and development of new immunosuppressants, a genetically distinct entity known as iatrogenic immunodeficiency-associated lymphoproliferative disorder (LPD) has emerged. Many of these cases arise following methotrexate use, challenging feasibility of standard HD-MTX regimens. The aim of this study was to further characterize this disorder and determine the optimal management strategy.</p><p><strong>Methods: </strong>We describe a case of a 76-year-old female with iatrogenic immunodeficiency-associated PCNSL successfully treated with surgical resection followed by an antiviral and rituximab based regimen. We then performed a systematic literature review and identified 58 cases of non-transplant iatrogenic immunodeficiency-associated LPD involving the CNS. We used a linear probability statistical model to determine correlations with outcome.</p><p><strong>Results: </strong>Natalizumab was associated with EBV negative tumors (<i>P</i> = .023), and EBV positive tumors were associated with improved outcomes (<i>P</i> = .016). Surgical resection was associated with improved outcomes (<i>P</i> = .032), although limited by potential confounding effect. Antiviral treatment (<i>P</i> = .095), rituximab (<i>P</i> = .111), and stem cell transplant (SCT) (<i>P</i> = .198) showed a trend toward improved outcomes. The remaining treatments including methotrexate showed no improvement.</p><p><strong>Conclusion: </strong>We propose that surgical resection, rituximab, and antiviral treatment may be considered as an alternative to standard HD-MTX based regimens when managing iatrogenic immunodeficiency-associated LPD of the CNS. Further study through prospective cohort studies or randomized clinical trials is warranted.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"169-175"},"PeriodicalIF":2.7,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9546597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}